Sanofi Consumer Healthcare India Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year ended December 31, 2025, with the stock exchanges. The filing, dated June 4, 2026, details the company's environmental, social, and governance (ESG) performance, highlighting a significant transition to renewable energy that resulted in zero Scope 1 and Scope 2 greenhouse gas emissions for the calendar year.

The company reported that it consumed 642.83 GJ of energy from renewable sources in CY 2025, compared to 3,449.09 GJ in the previous year. This shift to green energy at its new leased office premises contributed to the elimination of direct and indirect greenhouse gas emissions, which stood at 5.04 metric tonnes of CO2 equivalent in the prior year. The report notes that environmental data may not be directly comparable due to a change in operational boundaries and office relocation.

Environmental Performance

Sanofi Consumer Healthcare India Limited disclosed its waste management metrics, indicating a total waste generation of 5.08 metric tonnes in CY 2025, a decrease from 52.56 metric tonnes in CY 2024. The company achieved 100% recycling of the non-hazardous waste generated during the year. Water consumption totaled 935.22 kilolitres, with an intensity of 0.106 per rupee of turnover. The company also implemented initiatives such as energy-efficient sensors and water-saving fixtures, resulting in energy savings of up to 12% and water savings of 47.32%.

Social and Governance Metrics

The report provides detailed statistics on the company's workforce, which comprised 518 permanent employees and 79 permanent workers as of the end of the financial year. Women accounted for 18% of the permanent employee base and 4% of the permanent worker base. The company achieved 100% coverage for health and accident insurance for all permanent employees and workers. The Board of Directors included two women, representing 33% of the total six members.

The company reported one complaint regarding sexual harassment during CY 2025, which was resolved. There were zero instances of discrimination, child labour, or forced labour. The report also details the company's material responsible business conduct issues, identifying customer health and safety, data privacy, and regulatory compliance as key risks, with robust mitigation strategies in place.

Stakeholder Engagement and Operations

Sanofi Consumer Healthcare India Limited serves a diverse customer base across 29 states and 4 countries, with exports contributing 19% to total turnover. The company sourced 17% of its Active Pharmaceutical Ingredients sustainably and engaged with 100% of its value chain partners on ethical and compliance standards. The report confirms that the company has a dedicated management-level committee overseeing ESG matters, chaired by Managing Director Himanshu Bakshi.

Sanofi Consumer Healthcare India Limited reported a 21% increase in revenue from operations to ₹8,784 million for the financial year ended December 31, 2025. Profit after tax grew by 33% to ₹2,401 million, while return on capital employed stood at 62.5%. The company’s export business expanded its geographic footprint during the year.

The company’s performance reflects the strength of its brands, the effectiveness of its growth investments, and operational discipline. During the year, the company made deliberate investments behind its brands, supported by a synergistic demand-generation model that integrated Healthcare Professional (HCP) recommendation, consumer engagement, and retail availability.

Financial Performance

The company delivered a strong financial performance despite operating in a dynamic environment. The export business continued to gain momentum, expanding both geographic footprint and growth opportunities. This progress strengthens the diversification of the business and enhances the ability to leverage the strength of brands beyond India.

Strategic Initiatives

The company significantly expanded its engagement with doctors and specialists, doubling its face-to-face doctor reach and extending its digital HCP engagement to over 50,000 healthcare professionals. Consumer engagement initiatives reached approximately 60 million consumers through digital-first, multimedia campaigns.

The company also strengthened its innovation agenda with the launch of Allegra-D, a differentiated and efficacious solution that addresses an important consumer need. The launch reinforces the commitment to bringing science-backed innovations that deliver meaningful health outcomes for consumers.

Corporate Governance

The Board of Directors has recommended a final dividend of ₹75 per equity share of ₹10 each for the financial year ended December 31, 2025. The dividend is subject to the approval of members at the ensuing Annual General Meeting scheduled on June 26, 2026.

The company has appointed M/s. Price Waterhouse & Co Chartered Accountants LLP as the statutory auditors to fill the casual vacancy caused by the resignation of M/s. Kalyaniwalla & Mistry LLP. The appointment is subject to shareholder approval.